Thea Pharma

Focus: Thea Pharma is a public ophthalmic therapeutics company headquartered in Waltham, MA, focused on glaucoma, dry eye, and retinal disease treatments. The company generates approximately 50% of revenue from BETIMOL (timolol), a mature eye-drop franchise.

Ophthalmology

Profile data last refreshed 14h ago · AI intelligence enriched 3d ago

Funding Stage

PUBLIC

Open Jobs

About Thea Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow Thea Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

2 in 5yr

IYUZEH

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

BETIMOL

Glaucoma/ocular hypertension

$3M Part D

LOE Approaching

Flagship revenue driver (50% of company total) but approaching loss of exclusivity, creating immediate cash cliff pressure.

Help build intelligence for Thea Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep ophthalmic expertise with diversified portfolio across glaucoma, dry eye, and retinal conditions targeting underserved eye disease markets.
Recent FDA approval of ZOLYMBUS (bimatoprost gel, June 2026) signals active innovation pipeline with multiple Phase 2–3 programs in cataract, bacterial conjunctivitis, and dry eye.
Public company status provides equity upside, structured career progression, and stability absent in pre-clinical biotech.

Watch Out For

Revenue concentrated in mature, declining products: BETIMOL faces imminent LOE; ZIOPTAN expires 2029 and IYUZEH expires 2031, totaling $2.3M at-risk revenue requiring commercial reinvention.
Zero active hiring roles reported and minimal recent news velocity suggest organizational stasis or restructuring; unclear whether pipeline catalysts translate to headcount expansion.

Generated by Claude from Thea Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ZIOPTAN

Prostaglandin analog for glaucoma

$2M Part D

LOE Approaching2.8yr

Second-largest revenue contributor facing 2029 patent expiration; represents material cash flow cliff within 3–4 years.

COSOPT PF

Glaucoma (preservative-free formulation)

$893K Part D

Peak

Peak-stage combination therapy; preservative-free positioning differentiates from legacy COSOPT but declining utility as parent TIMOLOL loses exclusivity.

IYUZEH

Prostaglandin analog for glaucoma

$252K Part D

Peak4.9yr

Newer prostaglandin formulation; modest revenue but faces 2031 expiration within medium-term planning horizon.

COSOPT

Glaucoma

$135K Part D

LOE Approaching

Original (preserved) formulation of combination therapy; losing share to preservative-free variant and approaching generic erosion.

AZASITE

Bacterial eye infections

$67K Part D

LOE Approaching

Niche anti-infective with minimal revenue; approaching LOE with limited differentiation in crowded antibacterial category.

AKTEN

Topical ocular anesthetic

$1K Part D

Post-LOEPost-LOE

Generic-equivalent anesthetic with negligible revenue; post-LOE status indicates commoditized, non-strategic asset.

LIDOCAINE HYDROCHLORIDE

Topical anesthetic

Post-LOE

ANDA-approved generic formulation; non-revenue-generating commodity with no competitive differentiation.

ZOLYMBUS

Glaucoma/ocular hypertension

Launch9.8yr

Recently FDA-approved (June 2026) preservative-free gel formulation; represents highest-potential near-term pipeline success and extends bimatoprost IP to 2036.

TIMOLOL

Glaucoma/ocular hypertension

Post-LOE

ANDA-approved generic; non-revenue-contributing commodity asset in mature market.

Pipeline & Clinical Trials

T2762

Dry Eye Syndrome

N/A

Clinical Trials (1)

NCT02617095Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

N/A

Thealoz Duo

Dry Eye Disease

N/A

Clinical Trials (1)

NCT05356728Comparison of Two Types of Artificial Tears

N/A

T2259

Dry Eye Syndromes

N/A

Clinical Trials (1)

NCT03874429Efficacy of T2259 in DED

N/A

HYABAK®

Assess the Patient Feeling About the Handiness of Two Different Vials Used to Deliver Both, Unpreserved Hyaluronic Eye Drops

N/A

Clinical Trials (1)

NCT01546012Assessment of Patient's Satisfaction Regarding the Handiness of Two Hyaluronic Acid Eye Drops Vials

N/A

T2309

Healthy Adult Subjects

N/A

Clinical Trials (1)

NCT04596605Gastrointestinal Tolerance Assessment of T2309

N/A

T10070, Plastic tube with a roll-on applicator filled with an ointment

Healthy Volunteers

N/A

Clinical Trials (1)

NCT05622435Clinical Investigation to Evaluate the Tolerance of T10070 on Healthy Volunteers

N/A

Cosmetic: Blephaderm

Eyelid; Wound

N/A

Clinical Trials (1)

NCT07234292Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery.

N/A

Cacicol20

Corneal Erosion

N/A

Clinical Trials (1)

NCT03739255Facilitation of Corneal Re-epithelialization After Photorefractive Keratectomy

N/A

T2769

Dry Eye

N/A

Clinical Trials (1)

NCT05965778Performance and Safety of T2769 in DED

N/A

Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice

Palpebral Pathologies

N/A

Clinical Trials (1)

NCT01552174Management of Eyelid Disorders by Ophthalmologists in Usual Medical Practice

N/A

blood sample

Age-related Macular Degeneration

N/A

Clinical Trials (1)

NCT04482465Omega 3 and Vitamin D Dosage in a Population With Moderate to High Risk of AMD

N/A

Preservative free hyaluronic acid artificial tear

Evaporative Dry Eye

N/A

Clinical Trials (1)

NCT05536661Impact of Tear Substitute Use on Dry Eye in Gamers.

N/A

T7082

Age Related Macular Degeneration

N/A

Clinical Trials (1)

NCT04778436Macula Evolution in Patients With AMD Taking Oral Food Supplementation

N/A

T4020

Keratoconus

N/A

Clinical Trials (1)

NCT02979054Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking

N/A

Cacicol20

Corneal Dystrophy, Epithelial Basement Membrane

N/A

Clinical Trials (1)

NCT02373397Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy

N/A

Dorsal genital nerve stimulation

Stress Urinary Incontinence

N/A

Clinical Trials (1)

NCT05804552The Effect of Dorsal Genital Nerve Stimulation on Opening Urethral Pressure

N/A

Thealoz Duo

Dry Eye

N/A

Clinical Trials (1)

NCT04803240Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment

N/A

T2769

Dry Eye Syndrome

N/A

Clinical Trials (1)

NCT03830359Efficacy, Safety of T2769 in Dry Eye Disease

N/A

T2769

Dry Eye Disease (DED)

N/A

Clinical Trials (1)

NCT07007702Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease

N/A

Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®

Adherence to Glaucoma Therapy

N/A

Clinical Trials (1)

NCT07206628Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®

N/A

Single arm

Glaucoma

N/A

Clinical Trials (1)

NCT04552964Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma

N/A

T2769

Dry Eye Syndrome

N/A

Clinical Trials (1)

NCT06375499Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

N/A

Blephademodex

Demodex Blepharitis

N/A

Clinical Trials (1)

NCT04780165Efficacy and Tolerability of Blephademodex Wipes

N/A

Nutrof

Diabetic Retinopathy

N/A

Clinical Trials (1)

NCT04499820Effect of OMEGA3 Supplementation in Diabetic Retinopathy

N/A

Cyclosporin

Dry Eye Disease (DED)

N/A

Clinical Trials (1)

NCT07234318Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears

N/A

Retilut

Wet Macular Degeneration

N/A

Clinical Trials (1)

NCT04756310Study of Nutritional Supplementation in Patients With Unilateral Wet AMD

N/A

T2769

Dry Eye

N/A

Clinical Trials (1)

NCT05931861Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

N/A

Azithromycin

Eye Infections, Bacterial

PHASE_1

Clinical Trials (1)

NCT00356772Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

Phase 1

Warming goggles

Eyelid Diseases

PHASE_1

Clinical Trials (1)

NCT01190397Warming Efficiency of Warm Compresses Versus BLEPHASTEAM® in Eyelid Therapy

Phase 1

LT2420

Eyelid Diseases

PHASE_1

Clinical Trials (1)

NCT01086943Clinical Safety Study on an Eyelid Warming Device to Evaluate the Eyelid and Cornea Temperature in Healthy Volunteers

Phase 1

Azithromycin

Eye Infections, Bacterial

PHASE_1

Clinical Trials (1)

NCT00357383Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

Phase 1

Azithromycin

Eye Infections, Bacterial

PHASE_1

Clinical Trials (1)

NCT00356850Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

Phase 1

Azithromycin

Eye Infections, Bacterial

PHASE_1

Clinical Trials (1)

NCT00357539Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

Phase 1

Azithromycin

Eye Infections, Bacterial

PHASE_1

Clinical Trials (1)

NCT00357292Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

Phase 1

Bimatoprost Ophthalmic

Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT05729594Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Phase 1

Kinezodianone R hydrochloride

Glaucoma

PHASE_1_2

Clinical Trials (1)

NCT05389267Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Phase 1/2

QR-110

Leber's Congenital Amaurosis

PHASE_1_2

QR-110

Leber Congenital Amaurosis 10

PHASE_1_2

GV550

Acute Adenoviral Keratoconjunctivitis

PHASE_2

Clinical Trials (1)

NCT01156025Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis

Phase 2

RNA antisense oligonucleotide for intravitreal injection

Retinitis Pigmentosa

PHASE_2

T4090 0.2%

Glaucoma

PHASE_2

Clinical Trials (1)

NCT06394973Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Phase 2

Slit Lamp Examination

Moderate to Severe Vernal Keratoconjunctivitis

PHASE_2

Clinical Trials (1)

NCT07169695A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Phase 2

T2345

Primary Open Angle Glaucoma

PHASE_2

Clinical Trials (1)

NCT01494753Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension

Phase 2

Azithromycin

Blepharitis

PHASE_2

Clinical Trials (1)

NCT01089608Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis

Phase 2

Intravitreal Injection of Ultevursen

Retinitis Pigmentosa (RP)

PHASE_2

Food supplement

Dry Eye Syndromes

PHASE_2

Clinical Trials (1)

NCT00357201Efficacy of T1675 Versus Placebo in Patients With Bilateral Treated Moderate Dry Eye Syndrome

Phase 2

T1210

Seasonal Allergic Conjunctivitis

PHASE_2

Clinical Trials (1)

NCT01344083Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Phase 2

Ultevursen

Retinitis Pigmentosa

PHASE_2_3

QR-421a

Retinitis Pigmentosa

PHASE_2_3

sepofarsen

Leber Congenital Amaurosis 10

PHASE_3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2019

Portfolio: 10 approved products, 43 clinical trials

Top TAs: Ophthalmology, Cardiovascular, Immunology

Publications: 3 in PubMed

Portfolio Health

Launch1 (10%)

Peak2 (20%)

LOE Approaching4 (40%)

Post-LOE3 (30%)

10 total products

Therapeutic Area Focus

6 marketed1 pipeline

6 marketed

1 marketed

1 marketed

Marketed

Pipeline

Risk Signals

2 active drug shortages

No regulatory warnings or layoff history on record, but imminent patent cliffs and zero hiring activity elevate restructuring risk within 12–24 months.

Research Publications(3)

Recent peer-reviewed publications with author affiliations at this company

Preservative-Free versus Benzalkonium Chloride-Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial.

Clinical ophthalmology (Auckland, N.Z.)

2023

PMID:37674591

[Vernal keratoconjunctivitis].